In the rapidly evolving world of biotechnology, one innovation is quietly revolutionizing how we treat cancer and other complex diseases: Bispecific Antibodies (BsAbs). These dual-targeting powerhouses are set to disrupt the $100 billion monoclonal antibody market, and they’re doing it faster than anyone predicted. Imagine a single drug that can bind to two different...